Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2V617F mutation [5]

Leukemia

Volumn 21, Issue 9, 2007, Pages 2051-

  Go, R S ^a  

^a GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GUANOSINE; IMATINIB; JANUS KINASE 2; THYMINE;

BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENE MUTATION; GENE TRANSLOCATION; HUMAN; LETTER; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NUCLEIC ACID BASE SUBSTITUTION; PHILADELPHIA CHROMOSOME POSITIVE CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN TARGETING; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 34548141757     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404825     Document Type: Letter

References (7)

1. Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H et al. Polycythemia, associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 2007; 21: 1103-1104.
2. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and pre-existing myeloproliferative disorders. Br J Haematol 2005; 128: 734-736.
3. Scott LM, Campbell PJ, Baxter EJ, Todd T, Stephens P, Edkins S et al. The V617F JAK2 mutation is.uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders. Blood 2005; 106: 2920-2921.
4. Hussein K, Bock O, Seegers A, Flasshove M, Henneke F, Buesche G et al. Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation. Blood 2007; 109: 4106-4107.
5. Haq AU. Transformation of polycythemia vera to Ph-positive chronic myelogenous leukemia. Am J Hematol 1990; 35: 110-113.
6. Wahlin A, Golovleva I. Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia. Eur J Haematol 2003; 70 240-241.
7. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: A critical target in chronic myelogenous leukemia. Cancer Res 2006; 66: 6468-6472.